HK1202059A1 - Compounds for treating spinal muscular atrophy - Google Patents
Compounds for treating spinal muscular atrophyInfo
- Publication number
- HK1202059A1 HK1202059A1 HK15102568.1A HK15102568A HK1202059A1 HK 1202059 A1 HK1202059 A1 HK 1202059A1 HK 15102568 A HK15102568 A HK 15102568A HK 1202059 A1 HK1202059 A1 HK 1202059A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161582064P | 2011-12-30 | 2011-12-30 | |
PCT/US2012/071899 WO2013101974A1 (en) | 2011-12-30 | 2012-12-28 | Compounds for treating spinal muscular atrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202059A1 true HK1202059A1 (en) | 2015-09-18 |
Family
ID=48698624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102568.1A HK1202059A1 (en) | 2011-12-30 | 2015-03-13 | Compounds for treating spinal muscular atrophy |
Country Status (11)
Country | Link |
---|---|
US (2) | US9617268B2 (ko) |
EP (1) | EP2797592B1 (ko) |
JP (1) | JP6193881B2 (ko) |
KR (1) | KR102057351B1 (ko) |
CN (1) | CN104244944B (ko) |
BR (1) | BR112014016287B1 (ko) |
CA (1) | CA2861609C (ko) |
EA (1) | EA029984B1 (ko) |
HK (1) | HK1202059A1 (ko) |
MX (1) | MX352861B (ko) |
WO (1) | WO2013101974A1 (ko) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2809322B9 (en) | 2012-01-26 | 2019-10-30 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
HUE039779T2 (hu) | 2012-02-10 | 2019-02-28 | Ptc Therapeutics Inc | Vegyületek gerinc-izomsorvadás kezelésére |
US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
MD20150056A2 (ro) * | 2012-12-24 | 2015-09-30 | Ramot At Tel-Aviv University Ltd | Agenţi pentru tratarea bolilor genetice cauzate de mutaţii nonsens şi metode de identificare a acestora |
CN103360269B (zh) * | 2013-07-16 | 2015-07-08 | 临海市联盛化学有限公司 | 一种3-氯-2-氨基苯酚的制备方法 |
CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
WO2015095449A1 (en) * | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
KR102472711B1 (ko) | 2014-04-22 | 2022-12-01 | 우니페르시테트 바젤 | 트리아진, 피리미딘 및 피리딘 유도체의 신규한 제조방법 |
PL3143025T3 (pl) | 2014-05-15 | 2020-03-31 | F. Hoffmann-La Roche Ag | Związki do leczenia rdzeniowego zaniku mięśni |
US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
WO2015197503A1 (en) * | 2014-06-25 | 2015-12-30 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy |
CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
US20200262800A1 (en) * | 2015-11-16 | 2020-08-20 | Ptc Therapeutics, Inc. | Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof |
CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
US9895358B2 (en) * | 2016-02-23 | 2018-02-20 | Indiana University Research And Technology Corporation | Combination therapies for treatment of spinal muscular atrophy |
WO2018068759A1 (zh) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 |
WO2018098446A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Methods for modulating rna splicing |
WO2018226622A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
JP2020523365A (ja) | 2017-06-14 | 2020-08-06 | ピーティーシー セラピューティクス,インコーポレーテッド | Rnaスプライシングを改変する方法 |
CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
IL272413B (en) | 2017-08-04 | 2022-09-01 | Skyhawk Therapeutics Inc | Methods and compositions for fusion modulation |
CN111132981B (zh) * | 2017-09-22 | 2023-10-31 | 豪夫迈·罗氏有限公司 | 制备吡啶并[1,2-a]嘧啶-4-酮衍生物的方法 |
KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
MX2020014116A (es) | 2018-06-27 | 2021-06-15 | Reborna Biosciences Inc | Agente profilactico o terapeutico para atrofia muscular espinal. |
PE20211378A1 (es) | 2018-06-27 | 2021-07-27 | Ptc Therapeutics Inc | Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington |
EP3908308A4 (en) * | 2019-01-08 | 2023-03-22 | Texas Tech University System | SMALL MOLECULES ANALOGS OF THE E4ORF1 PROTEIN IN THE TREATMENT AND PREVENTION OF METABOLIC DISORDERS |
WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
KR20210135507A (ko) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
JP2022522553A (ja) * | 2019-03-01 | 2022-04-20 | イルミナ ケンブリッジ リミテッド | 環外アミン置換クマリン化合物およびそれらの蛍光標識としての使用 |
CN109943092A (zh) * | 2019-04-09 | 2019-06-28 | 浙江工业大学 | 具有高荧光量子产率的咪唑类香豆素类染料及其合成方法 |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
US11787796B2 (en) | 2019-09-18 | 2023-10-17 | Takeda Pharmaceutical Company Limited | Plasma Kallikrein inhibitors and uses thereof |
US11370803B2 (en) | 2019-09-18 | 2022-06-28 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
CN110862395B (zh) * | 2019-11-13 | 2020-09-29 | 株洲千金药业股份有限公司 | 一种制备他达拉非重要杂质的原料化合物的制备方法 |
CN114315807B (zh) * | 2022-01-05 | 2023-09-15 | 江南大学 | 一种吡啶鎓盐光引发剂及其制备方法和应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1020636B (de) | 1954-11-12 | 1957-12-12 | Geigy Ag J R | Verfahren zur Herstellung von 3-Phenyl-7-acylamino-cumarinen |
NL277683A (ko) | 1961-04-27 | |||
FR1320597A (fr) * | 1961-04-27 | 1963-03-08 | Geigy Ag J R | Nouvelles 3-phényl-7-pyrazolyl-coumarines, utilisables en particulier comme azurants optiques |
US3311636A (en) * | 1963-03-14 | 1967-03-28 | Upjohn Co | Organic chemical compounds and process |
DE1245306B (de) * | 1963-05-11 | 1967-07-27 | Bayer Ag | Aufhellungsmittel |
DE1794396C2 (de) | 1966-03-19 | 1975-04-10 | Bayer Ag, 5090 Leverkusen | Aufhellungsmittel |
CH505089A (de) * | 1968-08-23 | 1971-03-31 | Bayer Ag | Verfahren zur Herstellung von 3-substituierten-7-Aminocumarinen |
JPS5023687B2 (ko) | 1972-03-07 | 1975-08-09 | ||
CH620322B (de) * | 1976-03-26 | Ciba Geigy Ag | Verwendung von 3-phenyl-7-(v-triazol-2-yl)-cumarinen zum optischen aufhellen von organischen materialien. | |
FR2361680A1 (fr) | 1976-08-11 | 1978-03-10 | Du Pont | Plaques d'impression planographiques et leur preparation |
DE2807761A1 (de) * | 1978-02-23 | 1979-08-30 | Basf Ag | Cumarinderivate |
DE2815956A1 (de) * | 1978-04-13 | 1979-10-18 | Bayer Ag | Verfahren zur herstellung von in 2-stellung substituierten triazolen-1,2,3 |
DE2950291A1 (de) * | 1979-12-14 | 1981-06-19 | Basf Ag, 6700 Ludwigshafen | Neue cumarinverbindungen und verfahren zur herstellung von cumarinverbindungen |
JPS56140990A (en) | 1980-04-07 | 1981-11-04 | Showa Kagaku Kogyo Kk | 3-phenylcoumarin derivative bearing dicarbonylimide group |
DE3101141A1 (de) * | 1981-01-16 | 1982-09-02 | Bayer Ag, 5090 Leverkusen | Triazolylcumarinverbindungen, sowie deren herstellung und verwendung als optiche aufheller, scintillatoren und laserfarbstoffe |
JPS62267285A (ja) | 1986-05-16 | 1987-11-19 | Kyorin Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
ATE106566T1 (de) | 1989-11-21 | 1994-06-15 | Bayer Ag | Optischer biosensor. |
DE59010069D1 (de) * | 1989-11-21 | 1996-02-29 | Bayer Ag | Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte |
EP0448241A3 (en) | 1990-02-28 | 1992-03-04 | Konica Corporation | Light-sensitive silver halide photographic material |
CA2123740C (en) * | 1993-05-19 | 2002-12-17 | Hee-Gwon Chae | Electric vacuum cleaner |
JPH073179A (ja) | 1993-06-15 | 1995-01-06 | Nippon Kayaku Co Ltd | インクジェットプリント用インク組成物及びこれを用いる染色法 |
WO2003051841A2 (en) | 2001-12-14 | 2003-06-26 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
CN1180016C (zh) * | 2002-04-04 | 2004-12-15 | 中国石化上海石油化工股份有限公司 | 用于制造增白聚丙烯纤维的增白聚丙烯母粒 |
JP3714948B2 (ja) * | 2002-09-11 | 2005-11-09 | 呉羽化学工業株式会社 | アミン化合物及びその用途 |
US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
US8337941B2 (en) * | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
US20090312364A1 (en) | 2006-12-20 | 2009-12-17 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
EP2242754A1 (en) | 2008-02-05 | 2010-10-27 | NeuroSearch A/S | Novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
DE102008018132A1 (de) * | 2008-04-09 | 2009-10-15 | Henkel Ag & Co. Kgaa | Kationische Direktzieher und Mittel zum Färben von keratinhaltigen Fasern |
WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
CN102197109B (zh) | 2008-10-29 | 2014-05-14 | 默克专利股份有限公司 | 液晶显示器 |
EP2809322B9 (en) | 2012-01-26 | 2019-10-30 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
HUE039779T2 (hu) | 2012-02-10 | 2019-02-28 | Ptc Therapeutics Inc | Vegyületek gerinc-izomsorvadás kezelésére |
US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
-
2012
- 2012-12-28 EA EA201491296A patent/EA029984B1/ru not_active IP Right Cessation
- 2012-12-28 US US14/369,294 patent/US9617268B2/en not_active Ceased
- 2012-12-28 JP JP2014550478A patent/JP6193881B2/ja active Active
- 2012-12-28 CN CN201280071056.5A patent/CN104244944B/zh active Active
- 2012-12-28 BR BR112014016287-5A patent/BR112014016287B1/pt active IP Right Grant
- 2012-12-28 CA CA2861609A patent/CA2861609C/en active Active
- 2012-12-28 US US15/695,299 patent/USRE47689E1/en active Active
- 2012-12-28 EP EP12862080.4A patent/EP2797592B1/en active Active
- 2012-12-28 KR KR1020147021262A patent/KR102057351B1/ko active IP Right Grant
- 2012-12-28 WO PCT/US2012/071899 patent/WO2013101974A1/en active Application Filing
- 2012-12-28 MX MX2014007877A patent/MX352861B/es active IP Right Grant
-
2015
- 2015-03-13 HK HK15102568.1A patent/HK1202059A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140128310A (ko) | 2014-11-05 |
EA029984B1 (ru) | 2018-06-29 |
US20150119380A1 (en) | 2015-04-30 |
WO2013101974A1 (en) | 2013-07-04 |
CN104244944B (zh) | 2018-06-08 |
EP2797592B1 (en) | 2019-08-28 |
BR112014016287B1 (pt) | 2022-08-09 |
US9617268B2 (en) | 2017-04-11 |
JP6193881B2 (ja) | 2017-09-06 |
MX2014007877A (es) | 2015-01-16 |
EA201491296A1 (ru) | 2015-01-30 |
EP2797592A4 (en) | 2016-01-13 |
CN104244944A (zh) | 2014-12-24 |
USRE47689E1 (en) | 2019-11-05 |
CA2861609C (en) | 2021-02-16 |
JP2015504057A (ja) | 2015-02-05 |
EP2797592A1 (en) | 2014-11-05 |
BR112014016287A2 (pt) | 2017-07-04 |
WO2013101974A8 (en) | 2019-03-07 |
CA2861609A1 (en) | 2013-07-04 |
KR102057351B1 (ko) | 2019-12-18 |
MX352861B (es) | 2017-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254045B (en) | Compounds for the treatment of spinal muscular atrophy | |
HK1202059A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1202069A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1200056A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1202527A1 (en) | Compounds for treating spinal muscular atrophy | |
HRP20181190T1 (hr) | SPOJEVI KOJI SU KORISNI ZA LIJEČENJE AIDS-a | |
IL251796A0 (en) | Methods to suppress muscle atrophy | |
HK1215399A1 (zh) | 用於治療脊髓性肌萎縮的化合物 | |
EP2872493A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
HK1207299A1 (en) | Methods for inhibiting muscle atrophy | |
HK1201040A1 (en) | Method for treating osteoporosis | |
AP2013006988A0 (en) | Treatment for lipodystrophy | |
HRP20181649T1 (hr) | Metoda liječenja osteoporoze | |
GB201010359D0 (en) | Compounds for treating proliferative disorders | |
EP2753626A4 (en) | LLP2A-BISPHOSPHONATE CONJUGATES FOR THE TREATMENT OF OSTEOPOROSIS | |
EP2563353A4 (en) | COMPOUNDS FOR ANTIFUNGAL TREATMENT | |
GB201009495D0 (en) | Compounds for treating proliferative disorders | |
GB0901794D0 (en) | Compounds for treating muscular dystrophy |